Literature DB >> 12604532

Pharmacokinetics of intravenous acyclovir, zidovudine, and acyclovir-zidovudine in pregnant rats.

Stacy D Brown1, Michael G Bartlett, Catherine A White.   

Abstract

The pharmacokinetics and placental transfer of acyclovir and zidovudine monotherapies and acyclovir-zidovudine combination therapy were compared in the pregnant rat. Timed-pregnancy Sprague-Dawley rats were used for the study. Doses of 60 mg of each drug/kg of body weight in monotherapy and in combination therapy were given by intravenous bolus, and samples of maternal plasma, amniotic fluid, fetal tissue, and placental tissue were collected over a period of 8 h postdose. Concentrations of each drug in the various matrices were measured by high-performance liquid chromatography. All data were analyzed by using WinNonlin. A one-compartment model with first-order elimination was used to fit the AZT plasma data from the combination therapy rats, but the plasma data from the other groups were fit to a two-compartment model. Tissue data were analyzed by noncompartmental analysis to generate area-under-the-concentration-time-curve values. Implementation of the combination therapy altered the pharmacokinetics of each drug compared to its monotherapy pharmacokinetics. The combination of these two drugs may potentiate fetal and amniotic fluid exposures to each drug.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12604532      PMCID: PMC149315          DOI: 10.1128/AAC.47.3.991-996.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  40 in total

Review 1.  Placental transporters relevant to drug distribution across the maternal-fetal interface.

Authors:  V Ganapathy; P D Prasad; M E Ganapathy; F H Leibach
Journal:  J Pharmacol Exp Ther       Date:  2000-08       Impact factor: 4.030

2.  Determination of 3'-azido-2',3'-dideoxyuridine in maternal plasma, amniotic fluid, fetal and placental tissues by high-performance liquid chromatography.

Authors:  T N Clark; C A White; C K Chu; M G Bartlett
Journal:  J Chromatogr B Biomed Sci Appl       Date:  2001-05-05

3.  Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine.

Authors:  G B Elion; P A Furman; J A Fyfe; P de Miranda; L Beauchamp; H J Schaeffer
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

4.  Acyclovir in pregnancy registry: six years' experience. The Acyclovir in Pregnancy Registry Advisory Committee.

Authors:  E B Andrews; B C Yankaskas; J F Cordero; K Schoeffler; S Hampp
Journal:  Obstet Gynecol       Date:  1992-01       Impact factor: 7.661

5.  9-(2-hydroxyethoxymethyl) guanine activity against viruses of the herpes group.

Authors:  H J Schaeffer; L Beauchamp; P de Miranda; G B Elion; D J Bauer; P Collins
Journal:  Nature       Date:  1978-04-13       Impact factor: 49.962

6.  Determination of acyclovir in maternal plasma, amniotic fluid, fetal and placental tissues by high-performance liquid chromatography.

Authors:  Stacy D Brown; Catherine A White; Chung K Chu; Michael G Bartlett
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2002-06-05       Impact factor: 3.205

Review 7.  Plasma protein binding of drugs in pregnancy.

Authors:  E Perucca; A Crema
Journal:  Clin Pharmacokinet       Date:  1982 Jul-Aug       Impact factor: 6.447

8.  Human organic anion transporters and human organic cation transporters mediate renal antiviral transport.

Authors:  Michio Takeda; Suparat Khamdang; Shinichi Narikawa; Hiroaki Kimura; Yasuna Kobayashi; Toshinori Yamamoto; Seok Ho Cha; Takashi Sekine; Hitoshi Endou
Journal:  J Pharmacol Exp Ther       Date:  2002-03       Impact factor: 4.030

9.  Disposition of intravenous radioactive acyclovir.

Authors:  P de Miranda; S S Good; O L Laskin; H C Krasny; J D Connor; P S Lietman
Journal:  Clin Pharmacol Ther       Date:  1981-11       Impact factor: 6.875

10.  Drug binding to plasma proteins during human pregnancy and in the perinatal period. Studies on cloxacillin and alprenolol.

Authors:  L Herngren; M Ehrnebo; L O Boréus
Journal:  Dev Pharmacol Ther       Date:  1983
View more
  5 in total

1.  Valacyclovir suppressive therapy reduces plasma and breast milk HIV-1 RNA levels during pregnancy and postpartum: a randomized trial.

Authors:  Alison L Drake; Alison C Roxby; Francisca Ongecha-Owuor; James Kiarie; Grace John-Stewart; Anna Wald; Barbra A Richardson; Jane Hitti; Julie Overbaugh; Sandra Emery; Carey Farquhar
Journal:  J Infect Dis       Date:  2011-12-06       Impact factor: 5.226

2.  Development of a Population Pharmacokinetics-Based in vitro-in vivo Correlation Model for Drugs with Site-Dependent Absorption: the Acyclovir Case Study.

Authors:  Soyoung Shin; Tae Hwan Kim; Da Young Lee; Seung Eun Chung; Jong Bong Lee; Do-Hyung Kim; Beom Soo Shin
Journal:  AAPS J       Date:  2020-01-14       Impact factor: 4.009

Review 3.  Antiretroviral bioanalysis methods of tissues and body biofluids.

Authors:  Robin DiFrancesco; Getrude Maduke; Rutva Patel; Charlene R Taylor; Gene D Morse
Journal:  Bioanalysis       Date:  2013-02       Impact factor: 2.681

4.  Infant safety during and after maternal valacyclovir therapy in conjunction with antiretroviral HIV-1 prophylaxis in a randomized clinical trial.

Authors:  Alison L Drake; Alison C Roxby; James Kiarie; Barbra A Richardson; Anna Wald; Grace John-Stewart; Carey Farquhar
Journal:  PLoS One       Date:  2012-04-11       Impact factor: 3.240

5.  Toxic effect of acyclovir on testicular tissue in rats.

Authors:  Elham Movahed; Vahid Nejati; Rajabali Sadrkhanlou; Abbas Ahmadi
Journal:  Iran J Reprod Med       Date:  2013-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.